Log in
Create new account
home
boards
job center
archives
company monitor
cp wire
device news
pharmagather
advertise
contact us
Home
follow-on biologics
Blood Drug Woes Could Weigh on FDA and its Approval of New, Copycat Biologic Medicines
Blood Drug Woes Could Weigh on FDA and its Approval of New, Copycat Biologic Medicines
Forbes
Affymax
drug approvals
FDA
follow-on biologics
Omontys
News
Merck's Ditching of Aranesp Biosimilar Highlights Follow-on-Biologics Pitfalls
Seeking Alpha
Amgen
anemia
Aranesp
follow-on biologics
Merck
Teva Pharmaceuticals
»
5 comments
News
Pfizer's Future: Biotech Follow-ups
Seeking Alpha
follow-on biologics
Pfizer
»
1 comment
News
FTC Report on Follow-on Biologics Sparks Congressional Debate
PharmTech.com
follow-on biologics
FTC
»
Login
or
register
to post comments
news tags
Abbott Laboratories
Amgen
Arena Pharmaceuticals
AstraZeneca
Bayer
Biogen Idec
biotech
Boston Scientific
Bristol-Myers Squibb
cancer
Celgene
China
Dendreon
diabetes
earnings
Eli Lilly
Europe
FDA
generics
Genzyme
GSK
hepatitis C
investors
JNJ
lawsuits
layoffs
M&A
Management
Medtronic
Merck
Novartis
obesity
patents
Pfizer
prostate cancer
Roche
Sanofi
Teva Pharmaceuticals
vaccines
Vivus
more tags
Yahoo! Finance
Quote for ABT